![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KLHDC4 |
Gene summary for KLHDC4 |
![]() |
Gene information | Species | Human | Gene symbol | KLHDC4 | Gene ID | 54758 |
Gene name | kelch domain containing 4 | |
Gene Alias | KLHDC4 | |
Cytomap | 16q24.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8TBB5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54758 | KLHDC4 | HCC1_Meng | Human | Liver | HCC | 2.91e-45 | 2.57e-02 | 0.0246 |
54758 | KLHDC4 | HCC2_Meng | Human | Liver | HCC | 3.93e-06 | 6.36e-02 | 0.0107 |
54758 | KLHDC4 | HCC2 | Human | Liver | HCC | 5.50e-05 | 2.42e+00 | 0.5341 |
54758 | KLHDC4 | S014 | Human | Liver | HCC | 3.12e-04 | 2.52e-01 | 0.2254 |
54758 | KLHDC4 | S015 | Human | Liver | HCC | 2.28e-02 | 2.47e-01 | 0.2375 |
54758 | KLHDC4 | S016 | Human | Liver | HCC | 4.08e-02 | 1.81e-01 | 0.2243 |
54758 | KLHDC4 | S027 | Human | Liver | HCC | 5.76e-04 | 4.28e-01 | 0.2446 |
54758 | KLHDC4 | S028 | Human | Liver | HCC | 2.18e-15 | 5.51e-01 | 0.2503 |
54758 | KLHDC4 | S029 | Human | Liver | HCC | 8.91e-10 | 4.90e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KLHDC4 | SNV | Missense_Mutation | rs763027865 | c.1022G>A | p.Arg341His | p.R341H | Q8TBB5 | protein_coding | tolerated(0.12) | possibly_damaging(0.893) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KLHDC4 | SNV | Missense_Mutation | novel | c.622N>A | p.Val208Met | p.V208M | Q8TBB5 | protein_coding | deleterious(0.01) | benign(0.277) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
KLHDC4 | SNV | Missense_Mutation | novel | c.1142C>A | p.Pro381His | p.P381H | Q8TBB5 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
KLHDC4 | SNV | Missense_Mutation | novel | c.76T>C | p.Ser26Pro | p.S26P | Q8TBB5 | protein_coding | deleterious(0.02) | probably_damaging(0.916) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
KLHDC4 | SNV | Missense_Mutation | rs147954686 | c.887N>A | p.Arg296Gln | p.R296Q | Q8TBB5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
KLHDC4 | SNV | Missense_Mutation | novel | c.1197G>T | p.Lys399Asn | p.K399N | Q8TBB5 | protein_coding | tolerated(0.1) | probably_damaging(0.939) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KLHDC4 | SNV | Missense_Mutation | rs368139898 | c.262N>A | p.Gly88Ser | p.G88S | Q8TBB5 | protein_coding | deleterious(0.01) | possibly_damaging(0.723) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KLHDC4 | SNV | Missense_Mutation | novel | c.448T>C | p.Tyr150His | p.Y150H | Q8TBB5 | protein_coding | tolerated(0.06) | benign(0.145) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KLHDC4 | SNV | Missense_Mutation | c.353G>T | p.Arg118Met | p.R118M | Q8TBB5 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-DD-A73A-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
KLHDC4 | SNV | Missense_Mutation | c.308G>A | p.Arg103Lys | p.R103K | Q8TBB5 | protein_coding | tolerated(0.83) | benign(0.007) | TCGA-FV-A4ZQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |